Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1

被引:51
作者
Higazi, AAR
Mazar, A
Wang, JY
Reilly, R
Henkin, J
Kniss, D
Cines, D
机构
[1] HOSP UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104
[2] ABBOTT LABS,ABBOTT PK,IL 60064
[3] OHIO STATE UNIV,DEPT OBSTET & GYNECOL,DIV MATERNAL FETAL MED,COLUMBUS,OH 43210
关键词
D O I
10.1182/blood.V87.9.3545.bloodjournal8793545
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Urokinase-type plasminogen activator (UPA) is synthesized as single-chain protein (scuPA) with little intrinsic activity, scuPA is activated when it is converted to two-chain urokinase (tcuPA) by plasmin or when it binds as a single-chain molecule to its cellular receptor (uPAR). Previous data indicate that complexes between scuPA and its receptor have somewhat higher affinity for plasminogen than does tcuPA, The current study indicates that plasminogen activator activity of scuPA bound to recombinant, soluble uPAR (suPAR) is also fivefold less sensitive to inhibition by plasminogen activator type 1 (PAI-1) than is soluble or receptor-bound tcuPA, Binding of PAI-1 to suPAR/scuPA complexes is totally reversible and can be overcome by increasing the concentration of plasminogen, suggesting a competitive mechanism of inhibition (K-i = 18 nmol/L). Binding of scuPA to suPAR also retards its cleavage by plasmin. These results indicates that binding of single-chain urokinase to its receptor promotes its activity, retards its inhibition, and protects it from conversion to a two-chain form of the enzyme, a step that may precede its inactivation and clearance from cell surfaces, These results are consistent with a physiologic role for receptor-bound single-chain urokinase as a cellular plasminogen activator. (C) 1996 by The American Society of Hematology.
引用
收藏
页码:3545 / 3549
页数:5
相关论文
共 21 条
[1]  
ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644
[2]  
BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865
[3]   PLASMINOGEN ACTIVATORS, TISSUE DEGRADATION, AND CANCER [J].
DANO, K ;
ANDREASEN, PA ;
GRONDAHLHANSEN, J ;
KRISTENSEN, P ;
NIELSEN, LS ;
SKRIVER, L .
ADVANCES IN CANCER RESEARCH, 1985, 44 :139-266
[4]   STUDY OF THROMBOXANE AND PROSTACYCLIN METABOLISM IN AN INVITRO MODEL OF 1ST-TRIMESTER HUMAN TROPHOBLAST [J].
DISS, EM ;
GABBE, SG ;
MOORE, JW ;
KNISS, DA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 167 (04) :1046-1052
[5]  
ELLIS V, 1991, J BIOL CHEM, V266, P12752
[6]   KINETIC-ANALYSIS OF THE INTERACTIONS BETWEEN PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND BOTH UROKINASE AND TISSUE PLASMINOGEN-ACTIVATOR [J].
HEKMAN, CM ;
LOSKUTOFF, DJ .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1988, 262 (01) :199-210
[7]   BOVINE PLASMINOGEN-ACTIVATOR INHIBITOR-1 - SPECIFICITY DETERMINATIONS AND COMPARISON OF THE ACTIVE, LATENT, AND GUANIDINE-ACTIVATED FORMS [J].
HEKMAN, CM ;
LOSKUTOFF, DJ .
BIOCHEMISTRY, 1988, 27 (08) :2911-2918
[8]  
HEKMAN CM, 1985, J BIOL CHEM, V260, P11581
[9]   ENHANCEMENT OF THE ENZYMATIC-ACTIVITY OF SINGLE-CHAIN UROKINASE PLASMINOGEN-ACTIVATOR BY SOLUBLE UROKINASE RECEPTOR [J].
HIGAZI, AA ;
COHEN, RL ;
HENKIN, J ;
KNISS, D ;
SCHWARTZ, BS ;
CINES, DB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (29) :17375-17380
[10]  
KASAI S, 1985, J BIOL CHEM, V260, P2382